The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset

Abstract

Background: Although the incidence of neutropenic fever (FN) is estimated

Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients

“…We specifically focused on the costs of treating the patient with HAI from a hospital perspective, without taking into account the economic consequences of HAIs from a societal point of view. Mean nosocomial cost of HCAIs in oncology patients is reported in the range of USD 6,324 to 19,110 from different countries [9][10][11]. In this study, the mean nosocomial cost was found as 2,183.8 ± 1,187.8€, which was lower than findings elsewhere.…”

“…The estimated incidence density of healthcare-associated infections (HAIs) ranges from 11 to 21.8 per 1,000 patients-days [5][6][7]. The attributable length of stay to HAIs has been found to vary from 6.8 to 11.5 days, the attributable mortality from 4.9% to 26.3%and the attributable cost from £6,324 (Canadian dollar) to £19,110 (US dollar) per oncology patient with HAI [8][9][10][11][12][13].…”

Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia

“…22 Lingaratnam et al 23 reported an average length of stay of 6 days with a mean cost per FN episode of € 7,063. ¶Including therapeutic antibiotics.…”

A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment

“…The methodology for selection of hospital episodes associated with FN has been reported previously. 18 We determined length of hospital stay distribution and case-mix classification of Victorian hospitalised patients with solid tumours and FN for the 2008 calendar year, then extracted patient episodes which were comparable to length of stay parameters frequently reported in the literature for low-risk FN (mean duration of stay, 5.7-6.3 days; median, 5 days; range, 1-20 days). [10][11][12][19][20][21] For the estimated 7% of patients that would develop complications (i.e.…”